Have an emergency

Book a Lab Test

Explore Research

Request an Appointment

Skip to main content
Menu
Consensus-driven target product profiles for curative sickle cell disease gene therapies

High-quality, patient-centered
medical care

The imperative for increased investment for an HIV cure
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa
Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
Model-based evaluation of the interaction between ritonavirboosted atazanavir and rifampicin in Ugandan adults with HIV
Expanding access to long-acting HIV therapy in low-income and middle-income countries
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study
Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa
Efficacy and safety of B/F/TAF in treatmentnaïve and virologically suppressed people with HIV≥50 years of age: integrated analysis from six phase 3 clinical trials
Objectively Measured Physical Activity among People with and without HIV in Uganda: Associations with Cardiovascular Risk and Coronary Artery Disease
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled trial
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
Changes in the Lipidome Are Associated With Immune Activation and Subclinical Vascular Disease in Youth With Human Immunodeficiency Virus in Uganda
Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers
A miniaturized wash-free microfluidic assay for electrical impedance-based assessment of red blood cell-mediated microvascular occlusion
…So that’s why we hide, we don’t want them to know’— challenges to antiretroviral therapy adherence in Kampala, Uganda
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study
Two-drug regimens for the treatment of HIV in Africa

Ways To Support Our Work

Volunteer in our missionsGet In Touch
Questions about clinical research?
Contact Us
Close Menu